Key Takeaways for Ulcerative Colitis Management
Experts in gastroenterology share take-home messages for the management of ulcerative colitis.
Clinical Pearls for the Treatment of Ulcerative Colitis
David P. Hudesman, MD; Marla Dubinsky, MD; Ellen J. Scherl, MD; and Miguel Regueiro, MD, provide advice for physicians treating patients with ulcerative colitis.
Future Treatment Paradigms in Ulcerative Colitis
Drs David P. Hudesman, Ellen J. Scherl, Marla Dubinsky, and Miguel Regueiro, explore novel therapies in the pipeline and discuss approaches to optimizing sequencing and treatment selection for ulcerative colitis.
Sequencing Therapies in Ulcerative Colitis
Experts in gastroenterology discuss their approach to sequencing therapies in ulcerative colitis, considering safety, efficacy, and access to various treatment regimens and comment on challenges physicians may face when incorporating new therapies into clinical practice.
Ozanimod in Ulcerative Colitis
Ellen J. Scherl, MD, reviews data from the phase 3 True North study evaluating the use of ozanimod as induction and maintenance therapy for moderate to severe ulcerative colitis, and the panel shares their experience with ozanimod in clinical practice.
Challenges in UC Treatment
Ellen J. Scherl, MD, leads a discussion on challenges faced with traditional ulcerative colitis treatments.
Switching Therapies in Ulcerative Colitis
David P. Hudesman, MD, and expert panelists provide insight on optimizing the sequencing of therapies in ulcerative colitis and determining when a change in treatment is needed.
Role of JAK Inhibitors and S1P Receptor Modulators for UC Treatment
Marla Dubinsky, MD, discusses the role of S1P receptor modulators and JAK inhibitors for the treatment of ulcerative colitis.
UC Treatment: Anti-integrin Antibodies and Anti-interleukins
David P. Hudesman, MD, reviews the use of anti-integrin and anti-interleukin therapies for the management of ulcerative colitis.
Using 5-ASAs and Steroids for UC Treatment
Ellen J. Scherl, MD, comments on the limited role of mesalamine and steroids for moderate-to-severe ulcerative colitis treatment.
Approaching Ulcerative Colitis Treatment Selection
Marla Dubinsky, MD, emphasizes the role of shared decision-making and patient goals of therapy when approaching treatment selection for ulcerative colitis.
Impact of IBD on Quality of Life
Drs David P. Hudesman, Marla Dubinsky, and Ellen J. Scherl explore the impact of IBD and ulcerative colitis on a patient’s quality of life.
Disease Subtypes and Differential Diagnosis of UC and CD
Ellen J. Scherl, MD, highlights the different subtypes of ulcerative colitis and the differential diagnosis with Crohn’s disease.
Overview of Inflammatory Bowel Disease (IBD)
David P. Hudesman, MD, and Marla Dubinsky, MD, define symptoms and potential disease triggers for inflammatory bowel disease (IBD).
2 Clarke Drive Cranbury, NJ 08512